POLYVANTIS Flies High at Aircraft Interiors Expo 2025 With Breakthrough Material Solutions That Meet Critical Industry Needs

8.4.2025 08:00:00 CEST | Business Wire | Press Release

POLYVANTIS, a leading multi-material sheet and film solutions supplier, will present its comprehensive product portfolio for aircraft interiors and glazing solutions at the Aircraft Interiors Expo. POLYVANTIS offers a wide range of films, sheets, and semi-finished products made from polymethyl methacrylate (PMMA), polyphenylsulfone (PPSU), polyetherimide (PEI), and polycarbonate (PC) that meet the high demands placed on materials for the aviation industry. POLYVANTIS serves its global customer base with the renowned brands EUROPLEX®, LEXAN™ PC film and sheet, and PLEXIGLAS® PMMA semi-finished products under one roof.

“For decades, customers have relied on our brands for innovative material technologies, applications, and manufacturing processes to support the aircraft interiors industry,” said Peter Chedd, Director, Mass Transportation, Europe at POLYVANTIS. “We are proud to leverage our robust history and introduce our combined expertise as POLYVANTIS. Through products like ULTEM™ sheet and LEXAN™ F8000HR sheet, we push the boundaries of what’s possible for the aviation industry.”

POLYVANTIS offers the aviation industry a one-stop solution for various cabin applications, including seatbacks, armrests, magazine holders, tray tables, galley interiors, luggage racks, personal service units, and lighting. Through its expansive portfolio, POLYVANTIS is pleased to offer the largest compliant thermoplastic offering around the globe, meeting both OSU and FST.

LEXAN™ F8000HR Sheet – Lightweight Thermoplastic Sheet Meets OSU & FST Requirements

Adding to its robust portfolio, POLYVANTIS will introduce a new thermoplastic sheet product unlike anything else on the aircraft interiors market: LEXAN™ F8000HR Sheet. Based on LEXAN™ PC sheet technology and reinforced with glass fibers, LEXAN™ F8000HR sheet offers unrivaled performance, and value compared to other fully FST-compliant aircraft interior materials. This new sheet meets OSU (CS 25.853) and FST (FAR 25.853 (d) + App.F Part IV) requirements, making it an ideal choice for applications required to meet stringent fire resistance standards. LEXAN™ F8000HR sheet also exhibits exceptional thermoforming capabilities and boasts a lighter weight than other OSU-compliant materials.

ULTEM™ 1668A Sheet - Engineered for Multilayer Excellence

POLYVANTIS is proud to reintroduce ULTEM 1668A sheet to its portfolio. ULTEM 1668A sheet is an extruded polyetherimide sheet specifically designed for aircraft interiors applications. With a legacy spanning over 30 years, ULTEM sheet materials are relied upon for some of the most strenuous applications in aviation. ULTEM 1668A sheet is used in engineered applications requiring a multilayer approach for demanding interior applications due to its tremendous strength and compliance with common flame resistance, anti-smoke, and anti-toxicity standards. The sheet is lightweight, opaque, and fully compliant with OSU 65/65 heat release criteria, and FAA NBS smoke and flammability testing criteria.

Also featured at the show, POLYVANTIS proudly showcase the following products for the industry:

EUROPLEX® PPSU Sheet for large components in aircraft interiors.
EUROPLEX® F Polycarbonate Sheets - Easy to form and ideal for aviation lighting.
LEXAN™ Opaque FST-Compliant Sheets - Lightweight solutions for aircraft interiors.
LEXAN™ 55/55 Compliant Sheets reinforced with glass fibers for improved stiffness.
ULTEM™ 65/65 Compliant Sheets - Engineered for multilayer excellence.
PLEXIGLAS® Aviation Grades: high-performance for glazing and transparent applications.
PLEXIGLAS® Stretched Acrylic Sheets: superior impact resistance and performance.

To learn more about the POLYVANTIS portfolio for aviation, visit the POLYVANTIS booth at the Aircraft Interiors Show, from April 8 - 10 (Hall 6, Stand 6C51A).

¹ULTEM™ is a registered trademark of SABIC
²LEXAN™ is a registered trademark of SABIC

About POLYVANTIS

POLYVANTIS is a global, multi-material player with some of the most coveted and iconic brands in the industry – such as PLEXIGLAS® and ACRYLITE® for polymethylmethacrylate semi-finished products and LEXAN™ for polycarbonate sheets and films. With 1,500 employees and 15 production sites worldwide, POLYVANTIS offers unmatched global capabilities, providing customers with innovative solutions in sheets and films for the building and construction, electrical and electronics, automotive, air and rail, healthcare and security, and lighting and signage markets. To learn more about the latest at POLYVANTIS, follow us on LinkedIn or our website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407252235/en/

Contacts

Media Inquiries:

Amy Waterman
Director, Global Marketing Communications
amy.waterman@polyvantis.net

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom